Table 1. Univariate analysis of factors associated with PFS and OS.
| Factors | No. | Recurrent (%) | p-value | Death (%) | p-value | |
|---|---|---|---|---|---|---|
| Age at diagnosis (yr) | 0.368 | 0.848 | ||||
| ≤55 | 76 | 32 (42.1) | 24 (31.6) | |||
| >55 | 46 | 23 (50.0) | 15 (32.6) | |||
| Family history of malignancy | 0.843 | 0.702 | ||||
| Yes | 30 | 13 (45.7) | 9 (30.0) | |||
| None | 92 | 42 (43.3) | 30 (32.6) | |||
| Menopause | 0.753 | 0.395 | ||||
| Postmenopausal | 75 | 33 (44.0) | 23 (30.7) | |||
| Premenopausal | 47 | 22 (46.8) | 16 (34.0) | |||
| BMI | 0.880 | 0.888 | ||||
| ≤25 | 61 | 27 (44.3) | 18 (29.5) | |||
| >25 | 61 | 28 (45.9) | 21 (34.4) | |||
| Pretreatment CA125 level (U/mL) | 0.002 | 0.023 | ||||
| <244 | 55 | 18 (32.7) | 13 (23.6) | |||
| ≥244 | 52 | 30 (57.7) | 19 (36.5) | |||
| Ascites | 0.133 | 0.077 | ||||
| Negative | 68 | 27 (39.7) | 18 (26.5) | |||
| Positive | 49 | 25 (51.0) | 18 (36.7) | |||
| Tumor site | 0.001 | <0.001 | ||||
| Unilateral | 99 | 39 (39.4) | 26 (26.3) | |||
| Bilateral | 23 | 16 (69.6) | 13 (56.5) | |||
| Tumor volume (cm) | 0.139 | 0.038 | ||||
| <10 | 49 | 26 (53.1) | 21 (42.9) | |||
| ≥10 | 73 | 29 (39.7) | 18 (24.7) | |||
| Tumor stage | <0.001 | <0.001 | ||||
| I | 57 | 10 (17.5) | 5 (7.9) | |||
| II | 19 | 8 (42.1) | 6 (30.0) | |||
| III | 36 | 28 (77.8) | 25 (58.1) | |||
| IV | 10 | 9 (90.0) | 8 (80.0) | |||
| Residual disease (cm) | <0.001 | <0.001 | ||||
| R0 | 98 | 36 (36.7) | 23 (23.5) | |||
| ≤1 | 18 | 13 (72.2) | 10 (55.6) | |||
| >1 | 6 | 6 (100.0) | 6 (100.0) | |||
| Sensitivity to chemotherapy | <0.001 | <0.001 | ||||
| Sensitive | 81 | 14 (17.3) | 7 (8.6) | |||
| Insensitive | 40 | 40 (100.0) | 31 (77.5) | |||
| PD-L1 expression | 0.021 | 0.001 | ||||
| Low | 68 | 25 (36.8) | 13 (19.1) | |||
| High | 54 | 30 (55.6) | 26 (48.1) | |||
BMI, body mass index; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R0, no visible residual disease.